Enanta Pharmaceuticals (ENTA) Net Cash Flow (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Net Cash Flow data on file, last reported at -$2.5 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 89.86% year-over-year to -$2.5 million; the trailing twelve-month figure through Mar 2026 stood at -$25.3 million (down 542.24% YoY), and the FY2025 full-year result was -$5.5 million, up 88.49% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$2.5 million, down from $5.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $47.1 million in Q4 2024 and bottomed at -$58.1 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$2.5 million (2026), against an average of -$3.6 million.
• Peak annual rise in Net Cash Flow reached 337.52% in 2023, while the deepest fall reached 2466.63% in 2023.
• A 5-year view of Net Cash Flow shows it stood at -$1.8 million in 2022, then tumbled by 2466.63% to -$45.5 million in 2023, then jumped by 203.65% to $47.1 million in 2024, then sank by 89.09% to $5.1 million in 2025, then plunged by 148.82% to -$2.5 million in 2026.
• The last three Net Cash Flow figures came in at -$2.5 million (Q1 2026), $5.1 million (Q4 2025), and -$12.5 million (Q3 2025), per Business Quant data.

Peer Comparison